Top 10 GLP-1 Exercise and Workout Questions from Reddit, Answered

Question 1

Will resistance training actually preserve my muscle on a GLP-1?

Accepted Answer

The best-controlled trial to ask this question is S-LITE, a 1-year Danish trial that compared liraglutide 3.0 mg, supervised exercise, both combined, and placebo after an 8-week low-calorie diet (Lundgren 2021, PMID 33951361). The exercise-plus-liraglutide arm lost the most fat while preserving the most lean mass, and the lean-mass-to-fat-loss ratio was substantially better than the drug-only arm. The drug-alone group lost weight but a meaningfully larger share of that loss came from lean tissue compared with the exercise-plus-drug group. SURMOUNT-1 DXA substudy data on tirzepatide showed total fat-mass loss of about 33.9% on the 15 mg dose with lean-mass loss of about 10.9%, so the proportion of fat in the body fell (Look 2025, PMID 39996356). STEP 1 reported a similar pattern on semaglutide, with roughly 39% of total weight loss coming from lean mass and 61% from fat (Wilding 2021, PMID 33567185). Across these trials, adding 2-3 resistance sessions per week is associated with a smaller share of weight loss coming from lean tissue. None of this is medical advice.

Question 2

Why does my cardio feel so much harder on Wegovy or Zepbound?

Accepted Answer

Two mechanisms in the trial literature plausibly explain a harder-feeling cardio session. First, calorie intake on GLP-1s typically drops 30-40% during titration, so glycogen stores and same-day fuel availability are lower; STEP trials paired the drug with a 500 kcal deficit and patients commonly reported reduced energy at higher intensities (Wilding 2021, PMID 33567185). Second, a systematic review and meta-analysis of weight-lowering pharmacotherapies found that GLP-1 receptor agonists modestly increase walking capacity and self-reported physical function but the cardiorespiratory-fitness signal (VO2max) was variable and trial-dependent (Jobanputra 2023, PMID 36721366). Heart rate at a given workload often rises by 2-5 bpm on GLP-1s, a known class effect tracked across STEP and SURMOUNT. That means the same pace can feel like a higher effort even when objective fitness is unchanged. Dehydration on titration days makes it worse. The pattern on Reddit, consistent with the trials, is that cardio feels hardest in the first 2-4 weeks of each dose step and normalizes once intake and hydration adjust. None of this is medical advice.

Question 3

Can I actually build muscle while losing weight on semaglutide or tirzepatide?

Accepted Answer

Possible but difficult, and the trial evidence is mixed. The S-LITE combined arm produced the best body-composition outcome of any GLP-1 trial published to date, but it was lean-mass preservation, not net muscle gain, in most participants (Lundgren 2021, PMID 33951361). A retrospective analysis in Nutrients found that obesity and metabolic disease blunt the anabolic response to protein supplementation and resistance exercise, meaning the typical hypertrophy stimulus is less efficient in this population even without a GLP-1 (Nilsson 2024, PMID 39771028). The general resistance-training literature shows that net muscle gain in a 20-30% calorie deficit is uncommon in trained individuals; recomposition (small gains plus fat loss) is more typical in novice lifters or in patients returning to training. SURMOUNT-1 DXA data show that fat loss is much larger than lean loss in absolute terms, so the body-fat percentage falls even when scale weight drops (Look 2025, PMID 39996356). Reddit posts describing measurable muscle gain almost always involve a previously detrained patient progressing on basic compound lifts. None of this is medical advice.

Question 4

How much protein do I need on workout days while on a GLP-1?

Accepted Answer

Trial protocols and obesity-pharmacotherapy reviews converge on roughly 1.2-1.6 grams per kilogram of body weight per day during active weight loss, spread across 3-4 feedings, with the higher end favored on resistance-training days (Henney 2025, PMID 38710803). The STEP and SURMOUNT trials did not impose a high-protein diet; they paired the drug with a 500 kcal deficit and standard counseling, and the lean-mass losses observed (Wilding 2021, PMID 33567185; Look 2025, PMID 39996356) likely reflect that baseline. Across the S-LITE design, the exercise arms received structured training and standardized food intake, and lean-mass preservation was best in the combined drug-plus-exercise group (Lundgren 2021, PMID 33951361). Practically, on a GLP-1, hitting 1.2-1.6 g/kg requires deliberate planning because appetite is suppressed and the same volume of food now feels like a large meal. Per-meal targets of 30-40 g of protein are the common Reddit pattern, with a higher post-workout feeding. None of this is medical advice and individual needs vary.

Question 5

Why do I have zero energy at the gym after my Wegovy or Zepbound shot?

Accepted Answer

Two trial-level explanations dominate. First, intake drops sharply in the first 24-72 hours after each injection, because gastric emptying slows and appetite suppression peaks; STEP and SURMOUNT participants commonly described this as the most pronounced food-noise reduction window (Wilding 2021, PMID 33567185). Lower carbohydrate intake in those first days translates to lower muscle glycogen and a tougher high-intensity session. Second, the fitness data from a meta-analysis of weight-lowering drugs show modest improvements in walking capacity but no consistent improvement in peak exercise capacity early in treatment; cardiorespiratory benefits tend to emerge later as weight falls (Jobanputra 2023, PMID 36721366). Patients commonly time strength sessions to days 3-6 after injection rather than days 1-2, when food intake has typically resumed. The pattern is most pronounced during dose escalation steps (e.g., the week of going from 5 mg to 7.5 mg tirzepatide, or from 1.7 mg to 2.4 mg semaglutide) when GI symptoms also peak. None of this is medical advice.

Question 6

Should I time my GLP-1 injection around my workout schedule?

Accepted Answer

The FDA labels for semaglutide and tirzepatide do not specify injection timing relative to exercise, and no trial randomized patients to injection-versus-workout day combinations. What the trials do show is that GI side effects and reduced energy intake peak in the first 24-72 hours after injection, then taper through day 7 in most patients (Wilding 2021, PMID 33567185). For a once-weekly schedule, that means the lightest training day (mobility, low-intensity cardio, recovery) tends to align best with day 1-2 post-injection, and heavier resistance or interval work aligns better with days 4-7. SURMOUNT-1 data on body composition show that the larger fat-to-lean loss ratio depends mostly on overall protein intake and training stimulus over weeks, not on single-session timing (Look 2025, PMID 39996356). A 2026 pharmacology review specifically about GLP-1s and muscle strength flagged that older adults can experience disproportionate strength reductions during rapid weight loss and recommended pacing high-intensity training around the injection cycle (Prokopidis 2026, PMID 41577337). None of this is medical advice.

Question 7

Is my heart rate spike on cardio a sign something is wrong on Mounjaro or Zepbound?

Accepted Answer

A modest resting-heart-rate increase of 2-5 bpm is a documented class effect of GLP-1 receptor agonists across STEP and SURMOUNT trials, and it is one of the few cardiovascular signals that goes the 'wrong' direction even as blood pressure, lipids and inflammatory markers improve (Wilding 2021, PMID 33567185; Jastreboff 2022, PMID 35658024). The mechanism is not fully established but appears to involve autonomic modulation. The meta-analysis of physical-fitness outcomes confirmed the heart-rate-at-workload pattern but found no signal that exercise capacity or safety was reduced by the drug at maintenance doses (Jobanputra 2023, PMID 36721366). What that means in practice: a same-effort run at the same pace can produce a heart rate 5-10 bpm higher than pre-drug baseline. A heart rate that suddenly spikes 30+ bpm above expected, or angina, syncope, or palpitations on light exertion, is a different signal that warrants clinician attention regardless of the drug. None of this is medical advice; persistent or new cardiac symptoms are a clinician conversation.

Question 8

Will I lose my running endurance if I keep titrating up on Wegovy?

Accepted Answer

Endurance specifically (steady-state aerobic capacity) is the fitness domain that holds up best on GLP-1s, per the trial data. The systematic review of weight-lowering pharmacotherapies found that GLP-1 receptor agonists modestly increase 6-minute walk distance and self-reported physical function across populations (Jobanputra 2023, PMID 36721366). STEP 1 documented improvement in self-reported physical functioning subscores at week 68 alongside the 14.9% weight loss (Wilding 2021, PMID 33567185). Lower body weight at a given absolute pace means a lower relative effort; many runners on Reddit describe slower paces during titration weeks but faster paces by month 6-9 once weight is down 10-15%. The catch is fuel: chronic underfueling on a GLP-1 can degrade long-run performance even when short-distance pace improves. Marathon-distance training in particular requires a deliberate carbohydrate plan because appetite suppression makes it easy to under-eat on long-run days. None of this is medical advice; an experienced endurance athlete may want to discuss fueling strategy with a sports-medicine clinician.

Question 9

What should I do if I get lightheaded or dizzy during a workout on a GLP-1?

Accepted Answer

Lightheadedness during exercise on a GLP-1 most often reflects three reversible factors documented in the trial-safety data: dehydration (slowed gastric emptying plus reduced fluid intake), hypoglycemia (especially in patients also on insulin or sulfonylureas, less common on monotherapy), and orthostatic effects after rapid weight loss. STEP and SURMOUNT trial safety tables list dehydration-related adverse events at meaningfully higher rates on drug than on placebo (Wilding 2021, PMID 33567185; Jastreboff 2022, PMID 35658024). The 2026 review on GLP-1s and muscle strength also highlighted that rapid lean-mass loss in older adults can compromise stability and contribute to falls or dizziness during exertion (Prokopidis 2026, PMID 41577337). Practical patterns from the trials: front-load fluids and electrolytes on training days, eat at least 30-60 minutes before the session, and reduce intensity in the first week of any new dose step. Persistent dizziness, syncope, chest pain or palpitations during exercise are clinician signals regardless of the drug. None of this is medical advice.

Question 10

If I do not exercise at all on Wegovy or Zepbound, am I just going to lose all my muscle?

Accepted Answer

Not all of it, but a meaningful share of the weight loss will be lean tissue. The trial body-composition data are consistent: STEP 1 reported roughly 39% of total weight loss as lean mass and 61% as fat mass on semaglutide 2.4 mg, with patients not on a structured training program (Wilding 2021, PMID 33567185). SURMOUNT-1 DXA substudy showed fat-mass loss of about 33.9% and lean-mass loss of about 10.9% on tirzepatide 15 mg over 72 weeks, again without a structured training arm (Look 2025, PMID 39996356). The S-LITE trial directly contrasted exercise versus no-exercise arms and found lean-mass preservation was meaningfully better with structured training (Lundgren 2021, PMID 33951361). A 2026 review of GLP-1s in older adults flagged that the absolute decline in muscle strength can exceed what would be predicted from lean-mass loss alone, suggesting functional decline can outpace DXA numbers (Prokopidis 2026, PMID 41577337). Even low-volume resistance training (2 sessions a week) is associated with materially better body composition than no training. None of this is medical advice.

Questions and answers